Scholarlink

Background <p>Urologic tumors comprise about 20% of cancer diagnoses in Germany. To date, there are no studies with large datasets on the palliative situation of patients with urological tumors in the home environment, although dignified end-of-life care in the home environment is the wish of most cancer patients.</p> Methods <p>Data from 5125 patients who received specialized outpatient palliative care (SAPV) with an underlying urological cancer between 2017 and 2021 were included in the analysis.</p> Result <p>The analysis showed that 91.5% of patients died at home and the symptom burden remained stable or decreased slightly during treatment. The median survival time of patients receiving SAPV was 24&#xa0;days. Factors such as age, performance status, loss of appetite, weakness, and pain at the start of treatment influenced the survival time of the patients. Relatives were largely very satisfied with the care provided.</p> Conclusion <p>The study provides important insights into the palliative care of patients with urological tumors and underlines the importance of SAPV for dignified end-of-life care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Spezialisierte ambulante Palliativversorgung bei urologischen Tumoren

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月4日

查看全文
  • Stephan Degener,
  • Nici Markus Dreger,
  • Friedrich-Carl von Rundstedt,
  • Marie-Therese Schmitz,
  • Ulrich Grabenhorst,
  • Oliver Schmalz,
  • Klaus Weckbecker,
  • Johannes Just

摘要

Background

Urologic tumors comprise about 20% of cancer diagnoses in Germany. To date, there are no studies with large datasets on the palliative situation of patients with urological tumors in the home environment, although dignified end-of-life care in the home environment is the wish of most cancer patients.

Methods

Data from 5125 patients who received specialized outpatient palliative care (SAPV) with an underlying urological cancer between 2017 and 2021 were included in the analysis.

Result

The analysis showed that 91.5% of patients died at home and the symptom burden remained stable or decreased slightly during treatment. The median survival time of patients receiving SAPV was 24 days. Factors such as age, performance status, loss of appetite, weakness, and pain at the start of treatment influenced the survival time of the patients. Relatives were largely very satisfied with the care provided.

Conclusion

The study provides important insights into the palliative care of patients with urological tumors and underlines the importance of SAPV for dignified end-of-life care.